Table 5. Patients with T-cell ALL to be... | American Society of Hematology

Table 5.

Patients with T-cell ALL to be considered for alloHCT in first remission

	Indication*	Reference
1	Failure to achieve CR after induction	60
2	MRD >1 × 10⁻⁴ after 2 courses of therapy	30, 60
3	Presenting WCC >100 × 10⁹/L†	4
4	Complex cytogenetics ≥5 abnormalities	4, 30
5	Early T-cell precursor ALL†	9, 10, 17
6	Unfavorable N/F/PTEN/RAS genetics	29
7	Age 40-65 y, especially if delays occur in treatment due to toxicity	64

	Indication*	Reference
1	Failure to achieve CR after induction	60
2	MRD >1 × 10⁻⁴ after 2 courses of therapy	30, 60
3	Presenting WCC >100 × 10⁹/L†	4
4	Complex cytogenetics ≥5 abnormalities	4, 30
5	Early T-cell precursor ALL†	9, 10, 17
6	Unfavorable N/F/PTEN/RAS genetics	29
7	Age 40-65 y, especially if delays occur in treatment due to toxicity	64

TRM, treatment-related mortality.

Donor quality and the Hematopoietic Cell Transplantation Comorbidity index also affect the decision.⁶⁵ alloHCT may reduce relapse risk but this should be balanced against the predicted TRM.

†

MRD negativity may override these unfavorable prognostic factors.

View Large

This Feature Is Available To Subscribers Only